

(Use as many sheets as necessary)

Application Number	10/080,794
Filing Date	2/22/2002
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Karen Lacourciere
Attorney Docket Number	UBC P-020-3

Sheet	1	of	3	Attorney Docket Number	UBC.P-020-3
-------	---	----	---	------------------------	-------------

[illegible]

Examiner Initials*	Cite No.†	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [§]
		Country Code* -Number*- Kind Code* (if known)				
HPC 	X	WO 02/22835 A1	3/21/2002	ISIS Pharmaceuticals, Inc.	Appear	
	X	WO 03/062421 A1	7/31/2003	The University of British Columbia		
	X	WO 03/072591 A1	9/4/2003	The University of British Columbia		

Examiner Signature	<i>Thomas A. Cullen</i>	Date Considered	<i>10/1/2004</i>
--------------------	-------------------------	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OIPE JC4232
 APR 15 2004
 U.S. PATENT & TRADEMARK OFFICE

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
 Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete If Known

Application Number	10/080,794
Filing Date	2/22/2002
First Named Inventor	Gleave et al.
Art Unit	1635
Examiner Name	Karen Lacourciere
Attorney Docket Number	USC.P-020-3

Sheet 2 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AGC	X	GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, To Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58	
	X	GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, Page(s) 79-92, Volume 21	
	X	GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen-and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Number 2, XP 009021411	
	X	GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, Page(s) 209-221, Volume 4	
	X	JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34, XP002262319	
	X	MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-Independent PC-3 Prostate Cancer Cells Both <i>in Vitro</i> and <i>in Vivo</i> , Clinical Cancer Research, 5/1/2000, Page(s) 1655-1663, Volume 6	
	X	MIYAKE ET AL., Testosterone-repressed Prostate Message-2 is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer, Cancer Research, 1/1/2000, Page(s) 170-176, Volume 60	
	X	MIYAKE ET AL., Synergistic Chemosensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, Page(s) 4245-4252, Volume 7	
	X	MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, , Page(s) 337-349, Volume 8, Number 7,	
	X	ROSENBERG ET AL., Cluster: Physiologic and Pathophysiologic Considerations, International Journal of Biochemistry Cell Biology, Page(s) 633-645, Volume 27, Number 7	
	X	WILSON ET AL., Clusterin is a secreted mammalian chaperone, Trends in Biological Sciences, 3/1/2000, Page(s) 95-98, Volume 25, Number 3, XP004202536	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/1/2004
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Complete if Known	
	Application Number	10/080,794
	Filing Date	2/22/2002
	First Named Inventor	Gleave et al.
	Art Unit	1635
Examiner Name	Karen Lacourciere	
Attorney Docket Number	UBC.P-020-3	

Sheet (Use as many sheets as necessary) 3 of 3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
hgc	*	WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, Page(s) 917-925, Volume 227, Number 3, XP 001146404	
	*	ZANGEMEISTER-WITTKKE ET AL., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells¹, Clinical Cancer Research, 6/1/2000, Page(s) 2547-2555, Volume 6	
	*	ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved In Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental, 5/11/2001, Page(s) 934-940, Volume 298, Number 3	
	*	ZELLWEGER ET AL., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin¹, Neoplasia, , Page(s) 360-367, Volume 3, Number 4	

Examiner Signature		Date Considered	10/1/2004
--------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



RECEIVED

MAR 31 2003

Substitute for form 1449

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

TECH CENTER 1800/2800

7 / Suppl. I.D.S.
Application No.: 10/080,794
Applicant: Gleave, et al.
Filing Date: 02/22/2002
Conf. No.: 2924
Title: TRPM-2 Antisense Therapy
Attorney Docket No.:
UBC.P-020-3

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
Hoe	5,789,389	Tarasewicz et al.	08/04/1998
Hoe	6,335,194 B1	Bennett et al.	01/01/2002

FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
Hoe	WO 01/46455 A2	Yale University	06/28/2001

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	
Hoe	Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; Vol. 61; March 1, 2001; 2183-2188.
	Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; Vol. 99, No. 7; April 2, 2002; 4656-4661.
	Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; Vol. 27, 2000; 81-100.
	Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; Vol. 99, No. 7; April 2, 2002; 4349-4354.
	Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; Vol. 81, No.4; April 2001; 453-463.
	Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; Vol. 42; 1998; S3-S21.

RECEIVED

MAR 31 2003



Substitute for form 1449

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application No.: 10/080,794
Applicant: Gleave, et al. TECH CENTER 1800/2900
Filing Date: 02/22/2002
Conf. No.: 2924
Title: TRPM-2 Antisense Therapy
Attorney Docket No.:
UBC.P-020-3

Page 2 of 2

HCB	Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; Vol. 257; 2000; 101-110.
1	Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapoptotic Mediator; The Prostate Supplement; Vol. 9; 2000; 21-24.
	Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; www.genta.com ; 2001.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Shu Chuan Chen
Examiner Signature

10/1/2004
Date Considered



ATTORNEY DOCKET NO. UBC.P-020-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUN 26 2003
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Application No: 10/080,794
Filing Date: February 22, 2002
First Named Inventor: Gleave, et al.
Confirmation No.: 2924
Group Art Unit: 1635
Examiner Name: LaCourciere, Karen A.
Attorney Docket No.: UBC.P-020-3

FOREIGN PATENT DOCUMENTS

Examiner's Initials	office	Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear
Hcc	WO	00/49937 A2	The University of British Columbia	Aug. 31, 2000	

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner: *Shirley Calabrese* Date Considered: *10/11/2004*